NCT01056289 - Study Comparing Discontinuation Symptoms Of DVS SR In Subjects With Major Depressive Disorder (MDD) | Biotech Hunter

Enrollment

480

Participants

Timeline

Start Date

March 31, 2010

Primary Completion Date

February 28, 2011

Study Completion Date

February 28, 2011

Conditions

Major Depressive Disorder

Interventions

DRUG

Desvenlafaxine Succinate Sustained-Release Formulation 50 mg

DVS SR 50 mg Reference Group/Arm, oral tablet, 2 tablets/day during the first week and 1 tablet/day during weeks 2 through 4 of the double-blind treatment phase.

DRUG

Desvenlafaxine Succinate Sustained-Release Formulation 25 mg

DVS SR 25 mg Taper Group/Arm, oral tablet, 2 tablets/day during the first week and 1 tablet/day during weeks 2 through 4 of the double-blind treatment phase.

DRUG

Placebo

DVS SR Placebo Abrupt Discontinuation Group/Arm, oral tablet, 2 tablets/day during the first week and 1 tablet/day during weeks 2 through 4 of the double-blind treatment phase.